![](/img/cover-not-exists.png)
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial
Neil Fleshner, Leonard G. Gomella, Michael S. Cookson, Antonio Finelli, Andrew Evans, Samir S. Taneja, M. Scott Lucia, Eric Wolford, Matthew C. Somerville, Roger RittmasterVolume:
28
Year:
2007
Language:
english
Pages:
770
DOI:
10.1016/j.cct.2007.05.006
File:
PDF, 141 KB
english, 2007